公开(公告)号：US20250064843A1

公开(公告)日：2025-02-27

申请号：US18721283

申请日：2022-12-20

Applicant: 4B TECHNOLOGIES (BEIJING) CO., LIMITED ,  INSILICO MEDICINE IP LIMITED

Inventor： Bai Lu ,  Xiaoming Guan ,  Zavoronkovs Aleksandrs ,  Wing Frank Pun ,  Xi Long ,  Hei Man Liu ,  Ju Wang ,  Feng Ren

IPC: A61K31/706 ,  A61K31/203 ,  A61K31/343 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/519 ,  A61K31/55 ,  A61K31/567 ,  A61K38/13

Abstract: Provided is a method and a medicament for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof, comprising administering to the subject an effective amount of one or more active agents selected from the group consisting of a retinoic acid receptor alpha (RARα) agonist, a voltage-gated potassium channel (KCNB2) inhibitor, an adrenergic receptor α2B (ADRA2B) antagonist, a DNA methyltransferase 3 alpha (DNMT3A) antagonist, an insulin like growth factor 1 receptor (IGF1R) inhibitor, a mitogen-activated protein kinase 1 (MAPK1) inhibitor, a nitric oxide synthase 1 (NOS1) inhibitor, a glucocorticoid receptors (NR3C1) antagonist, and a peptidylprolyl Isomerase A (PPIA) antagonist.

公开(公告)号：US20250064825A1

公开(公告)日：2025-02-27

申请号：US18943124

申请日：2024-11-11

Applicant: ALKEM LABORATORIES LIMITED

Inventor： Akhilesh SHARMA ,  Babasaheb AWARE ,  Viraj SHAH ,  Amol AIWALE

IPC: A61K31/55 ,  A61K9/00 ,  A61K45/06 ,  A61K47/02 ,  A61K47/18 ,  A61K47/38

Abstract: The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.

公开(公告)号：US20250059188A1

公开(公告)日：2025-02-20

申请号：US18722104

申请日：2022-12-22

Applicant: Anaxis Pharma Pty Ltd

Inventor： Martin Brzozowski ,  Christophe Poitevin ,  Jean-Marc Daniel Garnier ,  Christopher Gardner ,  Guillaume Laurent Lessene ,  Peter Edward Czabotar ,  Carole Annie Schuster-Klein ,  Katherine Davies ,  Angus Cowan ,  Wilhelmus Johannes Antonius Kersten

IPC: C07D471/04 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  C07D487/04 ,  C07D491/08 ,  C07D519/00

Abstract: This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit MLKL.

公开(公告)号：US20250059179A1

公开(公告)日：2025-02-20

申请号：US18696948

申请日：2022-04-28

Applicant: AMGEN INC.

Inventor： Brian Alan Lanman ,  Ryan Paul Wurz ,  Wei Zhao ,  Xiaofen Li ,  Michael M. Yamano ,  Yunxiao Li ,  Ning Chen ,  Sebastian Leth-Petersen ,  Kexue Li ,  Liping Pettus ,  Rene Rahimoff ,  Primali Vasundera Navaratne ,  Huan Rui

IPC: C07D417/14 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10 ,  C07D487/20 ,  C07D498/04 ,  C07D498/10 ,  C07D519/00

Abstract: The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.

公开(公告)号：US20250059141A1

公开(公告)日：2025-02-20

申请号：US18720301

申请日：2022-12-16

Applicant: DUALITY BIOLOGICS (SUZHOU) CO., LTD.

Inventor： Yu ZHANG ,  Bing LI ,  Xi LI ,  Haiqing HUA ,  Zhongyuan ZHU

IPC: C07D223/16 ,  A61K31/437 ,  A61K31/55 ,  A61K31/553 ,  A61K31/675 ,  A61K31/69 ,  A61K47/68 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08 ,  C07D491/107 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00 ,  C07F5/02 ,  C07F9/553

Abstract: The present application relates to a TLR modulator and the use thereof. Specifically, the present application relates to a compound for modulating TLR activity, or a tautomer, a mesomer, a racemate, an enantiomer, a diastereoisomer, or a mixture form thereof, or a pharmaceutically acceptable salt thereof. The present application further relates to a method for preparing the compound of the present application and the use thereof.

公开(公告)号：US12220404B2

公开(公告)日：2025-02-11

申请号：US16932352

申请日：2020-07-17

Applicant: East Carolina University

Inventor： Stefan Clemens ,  Perrine Lallemand

IPC: A01N37/00 ,  A01N25/00 ,  A01N37/12 ,  A01N37/44 ,  A61K31/215 ,  A61K31/24 ,  A61K31/381 ,  A61K31/40 ,  A61K31/428 ,  A61K31/48 ,  A61K31/485 ,  A61K31/5383 ,  A61K31/55 ,  A61K45/06 ,  A61P43/00 ,  A61K9/00

Abstract: The present invention provides methods of treating Restless Legs Syndrome (RLS) including administering to a subject an effective amount of a dopamine D1 receptor antagonist. Compositions and kits useful for treating RLS are also provided.

公开(公告)号：US20250042910A1

公开(公告)日：2025-02-06

申请号：US18756256

申请日：2024-06-27

Applicant: Gilead Sciences, Inc.

Inventor： Elizabeth M. Bacon ,  Elbert Chin ,  Jeromy J. Cottell ,  Ashley Anne Katana ,  Darryl Kato ,  John O. Link ,  Nathan Shapiro ,  Teresa Alejandra Trejo Martin ,  Zheng-Yu Yang

IPC: C07D487/08 ,  A61K31/52 ,  A61K31/55 ,  A61K31/553 ,  A61K31/685 ,  A61K31/688 ,  A61K45/06 ,  A61P31/18 ,  C07C243/28 ,  C07C275/16 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  C07D471/08 ,  C07D487/10 ,  C07D491/04

Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

公开(公告)号：US20250042895A1

公开(公告)日：2025-02-06

申请号：US18697835

申请日：2022-10-06

Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

Inventor： Andrii MONASTYRSKYI ,  Derek DUCKETT ,  Alisa MOROZOVA ,  Sean CHIN CHAN

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/55 ,  C07D519/00

Abstract: The present disclosure provides compounds which find use as ULK1 inhibitors and their use in the treatment of medical disorders, in particular disorders associated with abnormal cellular proliferation such as cancers.

公开(公告)号：US20250042862A1

公开(公告)日：2025-02-06

申请号：US18709473

申请日：2022-11-10

Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Inventor： Bing XIONG ,  Jia LI ,  Tongchao LIU ,  Yubo ZHOU ,  Cong LI ,  Na LI ,  Weijuan KAN ,  Mingbo SU ,  Li SHENG ,  Xiaobei HU

IPC: C07D239/84 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/519 ,  A61K31/55 ,  A61P35/00 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/10

Abstract: Disclosed are an aromatic heterocyclic compound and an application thereof. The aromatic heterocyclic compound is represented by formula I, and the compound has good LSD1 enzyme inhibitory activity, and can be used as an LSD1 inhibitor for treatment of tumors etc.

公开(公告)号：US20250025449A1

公开(公告)日：2025-01-23

申请号：US18910248

申请日：2024-10-09

Applicant: Ovid Therapeutics Inc.

Inventor： Matthew During

IPC: A61K31/437 ,  A61K9/00 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/27 ,  A61K31/325 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/433 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/57 ,  A61K31/7048 ,  A61K45/06

Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.